Discover and read the best of Twitter Threads about #dishmanpharma
Most recents (1)
Niraparib,orally active small molecule PARP inhibitor developed by Tesaro to Rx ovarian cancer, granted fast track designtn by USFDA in 2016
Apr'20 USFDA approved Zejula (niraparib) as monotherapy maintenance Rx for ovarian,fallopian tube,peritoneal cancer
@GSK
#dishmanpharma
Apr'20 USFDA approved Zejula (niraparib) as monotherapy maintenance Rx for ovarian,fallopian tube,peritoneal cancer
@GSK
#dishmanpharma
Dishman Carbogen makes the API for the drug, has been supplying APIs to GSK from 2017
The approval will help Niraparib grow multifold,big positive for Dishmanās CRAMS business.
Niraparib API revenues for Dishman could grow twofold next 2 yrs
#dishmancarbogenamcis #DCAL #niraparib
The approval will help Niraparib grow multifold,big positive for Dishmanās CRAMS business.
Niraparib API revenues for Dishman could grow twofold next 2 yrs
#dishmancarbogenamcis #DCAL #niraparib
Zejula is currently approved as a maintenance therapy for adults with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and whose tumors have completely or partially responded to platinum-based chemotherapy treatments
Zejula sales $295 million 2019
#dcal
Zejula sales $295 million 2019
#dcal
